Correlation Between Novacyt SA and Vivos Therapeutics

Can any of the company-specific risk be diversified away by investing in both Novacyt SA and Vivos Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Novacyt SA and Vivos Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Novacyt SA and Vivos Therapeutics, you can compare the effects of market volatilities on Novacyt SA and Vivos Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Novacyt SA with a short position of Vivos Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Novacyt SA and Vivos Therapeutics.

Diversification Opportunities for Novacyt SA and Vivos Therapeutics

-0.56

Correlation Coefficient

Novacyt SA  Vivos Therapeutics

Excellent diversification

The 3 months correlation between Novacyt and Vivos is -0.56. Overlapping area represents the amount of risk that can be diversified away by holding Novacyt SA and Vivos Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vivos Therapeutics and Novacyt SA is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Novacyt SA are associated (or correlated) with Vivos Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vivos Therapeutics has no effect on the direction of Novacyt SA i.e., Novacyt SA and Vivos Therapeutics go up and down completely randomly.

Pair Corralation between Novacyt SA and Vivos Therapeutics

Assuming the 90 days horizon Novacyt SA is expected to under-perform the Vivos Therapeutics. But the pink sheet apears to be less risky and, when comparing its historical volatility, Novacyt SA is 1.08 times less risky than Vivos Therapeutics. The pink sheet trades about -0.11 of its potential returns per unit of risk. The Vivos Therapeutics is currently generating about 0.17 of returns per unit of risk over similar time horizon. If you would invest  293.00  in Vivos Therapeutics on September 21, 2024 and sell it today you would earn a total of  173.00  from holding Vivos Therapeutics or generate 59.04% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Novacyt SA  vs.  Vivos Therapeutics

Novacyt SA

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Novacyt SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Vivos Therapeutics

Risk-Adjusted Performance

13 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Vivos Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively conflicting basic indicators, Vivos Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Novacyt SA and Vivos Therapeutics

The main advantage of trading using opposite Novacyt SA and Vivos Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Novacyt SA position performs unexpectedly, Vivos Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vivos Therapeutics will offset losses from the drop in Vivos Therapeutics' long position.

The idea behind Novacyt SA and Vivos Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.